Literature DB >> 9681891

Magnetic resonance imaging (MRI) for localization of the prostatic apex: comparison to computed tomography (CT) and urethrography.

M Milosevic1, S Voruganti, R Blend, H Alasti, P Warde, M McLean, P Catton, C Catton, M Gospodarowicz.   

Abstract

BACKGROUND AND
PURPOSE: It is necessary to include the entire prostate in the high dose treatment volume when planning radical radiation for patients with prostate cancer. We prospectively compared magnetic resonance imaging (MRI) to computed tomography (CT) and urethrography as means of localizing the prostatic apex.
MATERIALS AND METHODS: Thirty patients with clinically localized prostate cancer had a sagittal T2-weighted MRI scan and a conventional axial CT scan performed in the treatment position prior to the start of radiotherapy. Twenty of these patients had a static retrograde urethrogram performed at simulation. The position of the MRI and CT apices were localized independently by two radiation oncologists. In addition, the MRI apex was localized independently by a diagnostic radiologist. The urethrogram apex, defined as the tip of the urethral contrast cone, was easily identified and was therefore localized by only one observer.
RESULTS: There was good interobserver agreement in the position of the MRI apex. Interobserver agreement was significantly better with MRI than with CT. There were no systematic differences in the position of the MRI and CT apices. However, the MRI apex was located significantly above and behind the urethrogram apex. There was poor correlation between MRI and CT and between MRI and urethrogram in the height of the apex above the ischial tuberosities. There was 83% agreement between MRI and CT and 80% agreement between MRI and urethrogram in the identification of patients with a low-lying apex. The apex, as determined by MRI, was <2 cm above the ischial tuberosities and therefore potentially under-treated in 17% of the patients.
CONCLUSIONS: MRI is superior to CT and urethrography for localization of the prostatic apex. All patients undergoing radiotherapy for prostate cancer should have localization of the apex using MRI or a technique of equal precision to assure adequate dose delivery to the entire prostate and to minimize the unnecessary irradiation of normal tissues.

Entities:  

Mesh:

Year:  1998        PMID: 9681891     DOI: 10.1016/s0167-8140(97)00232-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  16 in total

1.  Automated computer-derived prostate volumes from MR imaging data: comparison with radiologist-derived MR imaging and pathologic specimen volumes.

Authors:  Julie C Bulman; Robert Toth; Amish D Patel; B Nicolas Bloch; Colm J McMahon; Long Ngo; Anant Madabhushi; Neil M Rofsky
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

Review 2.  Role of magnetic resonance imaging and magnetic resonance spectroscopic imaging before and after radiotherapy for prostate cancer.

Authors:  Antonio C Westphalen; David A McKenna; John Kurhanewicz; Fergus V Coakley
Journal:  J Endourol       Date:  2008-04       Impact factor: 2.942

Review 3.  The future of image-guided radiotherapy will be MR guided.

Authors:  Julianne M Pollard; Zhifei Wen; Ramaswamy Sadagopan; Jihong Wang; Geoffrey S Ibbott
Journal:  Br J Radiol       Date:  2017-03-29       Impact factor: 3.039

4.  640-slice DVCT multi-dimensionally and dynamically presents changes in bladder volume and urine flow rate.

Authors:  Yunshan Su; Kewei Fang; Chongwen Mao; Shutian Xiang; Jin Wang; Yingwen Li
Journal:  Exp Ther Med       Date:  2017-12-22       Impact factor: 2.447

5.  Penile bulb sparing in prostate cancer radiotherapy : Dose analysis of an in-house MRI system to improve contouring.

Authors:  F Böckelmann; M Hammon; S Lettmaier; R Fietkau; C Bert; F Putz
Journal:  Strahlenther Onkol       Date:  2018-10-12       Impact factor: 3.621

6.  Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled.

Authors:  Kris T Huang; Radka Stoyanova; Gail Walker; Kiri Sandler; Matthew T Studenski; Nesrin Dogan; Tahseen Al-Saleem; Mark K Buyyounouski; Eric M Horwitz; Alan Pollack
Journal:  Radiother Oncol       Date:  2015-05-08       Impact factor: 6.280

7.  Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer.

Authors:  Ibrahim Karademir; Dinggang Shen; Yahui Peng; Shu Liao; Yulei Jiang; Ambereen Yousuf; Gregory Karczmar; Steffen Sammet; Shiyang Wang; Milica Medved; Tatjana Antic; Scott Eggener; Aytekin Oto
Journal:  AJR Am J Roentgenol       Date:  2013-11       Impact factor: 3.959

8.  Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis.

Authors:  Sungmin Woo; Sangwon Han; Tae-Hyung Kim; Chong Hyun Suh; Antonio C Westphalen; Hedvig Hricak; Michael J Zelefsky; Hebert Alberto Vargas
Journal:  AJR Am J Roentgenol       Date:  2019-12-04       Impact factor: 3.959

9.  Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning.

Authors:  Lucia Perna; Cesare Cozzarini; Eleonora Maggiulli; Gianni Fellin; Tiziana Rancati; Riccardo Valdagni; Vittorio Vavassori; Sergio Villa; Claudio Fiorino
Journal:  Radiat Oncol       Date:  2011-09-24       Impact factor: 3.481

10.  Urethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging.

Authors:  Ima Paydar; Brian S Kim; Robyn A Cyr; Harriss Rashid; Amna Anjum; Thomas M Yung; Siyuan Lei; Brian T Collins; Simeng Suy; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Front Oncol       Date:  2015-09-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.